10X Capital Venture Acquisition Corp. III
- Tickers
- None listed
- Headquarters
- Not recorded
- SEC CIK
- 0001848948
- Website
- Not recorded
Closing prices
This company has no stock ticker on record, so there are no prices to show.
Drugs
No drugs from this company are tracked yet.
FDA-approved applications
No Drugs@FDA application has a sponsor name that matches this company.
Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
| Metric | Reported value | Period | Filing |
|---|---|---|---|
| Revenue | Not reported in XBRL filings since 2015 | ||
| Net income (loss) | −2,291,057 USD | 1 Jul 2023 to 30 Sep 2023 FY2023 Q3 | 10-Q for Net income (loss) on sec.gov (opens in a new tab)Filed |
| Research and development expense | Not reported in XBRL filings since 2015 | ||
| Operating expenses | Not reported in XBRL filings since 2015 | ||
| Cash and cash equivalents | 646,847 USD | At 30 Sep 2023 FY2023 Q3 | 10-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed |
| Short-term investments and marketable securities | Not reported in XBRL filings since 2015 | ||
| Total liabilities | 19,803,951 USD | At 30 Sep 2023 FY2023 Q3 | 10-Q for Total liabilities on sec.gov (opens in a new tab)Filed |
| Stockholders' equity | −18,879,143 USD | At 30 Sep 2023 FY2023 Q3 | 10-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed |
| Common shares outstanding (cover page) | Not reported in XBRL filings since 2015 | ||
History
| Period | Reported value | Filing |
|---|---|---|
| 1 Jul 2023 to 30 Sep 2023 FY2023 Q3 | −2,291,057 USD | 10-Q filed 27 Nov 2023 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2023 to 30 Jun 2023 FY2023 Q3 | −1,782,427 USD | 10-Q filed 27 Nov 2023 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2023 to 31 Mar 2023 FY2023 Q3 | 2,775,197 USD | 10-Q filed 27 Nov 2023 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2022 to 31 Dec 2022 FY2022 | 698,292 USD | 10-K/A filed 22 May 2023 on sec.gov (opens in a new tab)Filed |
| 1 Jul 2022 to 30 Sep 2022 FY2023 Q3 | 1,111,967 USD | 10-Q filed 27 Nov 2023 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2022 to 30 Jun 2022 FY2023 Q3 | −112,593 USD | 10-Q filed 27 Nov 2023 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2022 to 31 Mar 2022 FY2023 Q3 | −347,368 USD | 10-Q filed 27 Nov 2023 on sec.gov (opens in a new tab)Filed |
| 10 Feb 2021 to 31 Dec 2021 FY2022 | −44,607 USD | 10-K/A filed 22 May 2023 on sec.gov (opens in a new tab)Filed |
Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.
Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
No recent headlines mention this company.
Insider transactions
All rows for 10X Capital Venture Acquisition Corp. III on Insider TradesLast 90 days of Form 4 filings, from 15 Aug 2026 (US Eastern dates).
- Buys code P
- None in this period
- Sells code S
- None in this period
- Other all other codes
- None in this period
Last transaction: none stored
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.